Bayer proposes $7.25 billion plan to settle Roundup cancer cases

Bayer, the German pharmaceutical and agrochemical company, announced Tuesday that its Monsanto subsidiary has proposed a nationwide class action settlement totaling up to $7.25 billion. The proposed settlement aims to resolve current and future claims alleging that Roundup weedkiller caused cancer, specifically non-Hodgkin lymphoma.

Roundup Litigation and the Proposed Settlement

The proposed settlement, expected to be filed in state court in St. Louis, Missouri, would establish a long-term claims program funded by capped annual payments over a period of up to 21 years. This move comes as Bayer faces approximately 65,000 lawsuits in U.S. State and federal courts from individuals who claim Roundup exposure led to their cancer diagnoses.

Did You Know? Bayer acquired Roundup as part of its $63 billion purchase of Monsanto in 2018.

Bayer CEO Bill Anderson expressed confidence that the settlement will resolve the vast majority of claims, though the number of current supporters of the deal remains undisclosed. The company has also reached confidential settlements with specific law firms, the details of which have not been publicly released.

Previous Settlements and Ongoing Legal Battles

This isn’t Bayer’s first attempt to address Roundup-related lawsuits. The company previously paid approximately $10 billion to settle most pending cases as of 2020, but that settlement did not cover future claims. Bayer has experienced mixed results in trials, winning some cases but also facing substantial jury awards, including a $2.1 billion verdict in Georgia in March.

Expert Insight: The proposed settlement represents a significant attempt by Bayer to manage the financial and reputational risks associated with the ongoing Roundup litigation, particularly as the company awaits a Supreme Court decision that could further shape its liability.

The company anticipates its provisions and litigation liabilities will increase from 7.8 billion euros ($9.24 billion) to 11.8 billion euros, with around 5 billion euros in litigation-related payouts expected in 2026. This is projected to result in negative free cash flow for the year, prompting Bayer to postpone the publication of its 2025 results and 2026 guidance until March 4.

Supreme Court Involvement

The proposed settlement coincides with the U.S. Supreme Court’s agreement to hear an appeal in a Roundup case. Bayer argues a favorable ruling in this case would significantly limit its liability, potentially wiping out several large verdicts and preventing future claims from those who opt out of the nationwide settlement. Oral arguments are scheduled for the end of April.

Frequently Asked Questions

What is Roundup?

Roundup is among the most widely used weedkillers in the United States.

What is the basis of the lawsuits against Monsanto/Bayer?

Plaintiffs allege they developed non-Hodgkin lymphoma and other forms of cancer due to using the Roundup weedkiller, either at home or on the job.

Does Bayer believe Roundup is safe?

Bayer has stated that decades of studies have shown Roundup and its active ingredient, glyphosate, are safe for human use.

As the legal landscape continues to evolve, will this settlement ultimately provide closure for those affected by Roundup exposure?